Pulmonary Embolism Therapeutics - Global Strategic Business Report

The global market for Pulmonary Embolism Therapeutics was valued at US$22.1 Billion in 2025 and is projected to reach US$47.5 Billion by 2032, growing at a CAGR of 11.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Pulmonary Embolism Therapeutics Market - Key Trends & Drivers Summarized

Why Is Pulmonary Embolism Therapy Becoming a Priority in Acute and Preventive Care Frameworks?

Pulmonary embolism (PE), characterized by a blockage in the pulmonary arteries due to a blood clot, represents one of the most life-threatening cardiovascular emergencies globally. Despite its high morbidity and mortality rates, PE is frequently underdiagnosed due to its varied clinical presentation, ranging from asymptomatic episodes to sudden death. Advances in imaging techniques, improved diagnostic algorithms, and increased clinical awareness have led to rising incidence rates-necessitating scalable and stage-specific therapeutic options.

The management of PE spans acute intervention, stabilization, and long-term recurrence prevention. Treatment regimens are driven by risk stratification models such as the Pulmonary Embolism Severity Index (PESI), determining whether patients require hospitalization or outpatient care. High-risk PE patients, particularly those with hemodynamic instability, are often managed with systemic thrombolysis or catheter-directed thrombolysis. The standard of care for most low to intermediate-risk cases includes anticoagulant therapy with agents such as low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), or unfractionated heparin (UFH).

Which Drug Classes and Intervention Technologies Are Shaping the Current Treatment Landscape?

Anticoagulants remain the cornerstone of pulmonary embolism therapy. The transition from traditional Vitamin K antagonists like warfarin to DOACs such as rivaroxaban, apixaban, and edoxaban has transformed outpatient management by offering fixed dosing, reduced monitoring, and fewer dietary interactions. These agents are now preferred for the majority of non-massive PE cases and have demonstrated comparable efficacy with better safety profiles. LMWH is still widely used in initial hospital-based care and in special populations such as cancer patients and pregnant women.

Thrombolytic therapy, while effective in dissolving clots, carries a significant risk of bleeding and is generally reserved for high-risk PE with right ventricular dysfunction. Newer catheter-directed thrombolysis systems, such as the EKOS endovascular system, deliver targeted thrombolytics directly to the clot, minimizing systemic exposure. Mechanical thrombectomy devices are being deployed in select cases to remove large clots with reduced hemorrhagic risk. Inferior vena cava (IVC) filters, although controversial due to complications, are occasionally used in patients with contraindications to anticoagulation. The development of hybrid protocols combining pharmacological and interventional therapies is becoming increasingly common.

How Are Clinical Guidelines, Patient Stratification, and Health System Protocols Influencing Market Trends?

Updated clinical guidelines from bodies such as the American College of Chest Physicians (ACCP), European Society of Cardiology (ESC), and National Institute for Health and Care Excellence (NICE) emphasize early discharge, outpatient management, and personalized treatment planning. These protocols reflect advances in diagnostic tools, including D-dimer assays, CT pulmonary angiography, and point-of-care ultrasound, which facilitate rapid risk assessment and triaging. The emergence of PE response teams (PERTs) in hospitals is also transforming decision-making by bringing together multidisciplinary teams to optimize individualized care.

Further, health systems are adopting digital tools for anticoagulant dose tracking, adherence monitoring, and telehealth consultations-especially important in chronic PE or post-discharge settings. Registries such as the International Cooperative Pulmonary Embolism Registry (ICOPER) and RIETE provide valuable real-world data on treatment outcomes and guide evidence-based refinements in care standards. Special attention is being directed toward long-term complications such as chronic thromboembolic pulmonary hypertension (CTEPH), which necessitates surgical or balloon pulmonary angioplasty interventions.

What Factors Are Driving the Growth of the Global Pulmonary Embolism Therapeutics Market?

The growth in the global pulmonary embolism therapeutics market is driven by increasing incidence of thromboembolic events, rising adoption of DOACs, and expansion of interventional technologies. Sedentary lifestyles, obesity, malignancies, and post-operative complications are contributing to the growing burden of venous thromboembolism (VTE), with PE accounting for a significant share of emergency admissions worldwide. Improved awareness among healthcare professionals and patients has led to earlier detection and broader treatment coverage.

Pharmaceutical innovation continues to shape market expansion. Pipeline candidates targeting Factor XI and Factor XII pathways aim to reduce thrombotic risk with minimal bleeding complications, which could further improve treatment options for vulnerable populations. Additionally, AI-powered diagnostic tools and predictive analytics platforms are being tested to identify high-risk individuals proactively. Healthcare infrastructure development in emerging economies is expanding access to timely PE diagnosis and management.

Key industry participants include Bayer AG, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Johnson & Johnson (Janssen), Inari Medical, and Penumbra Inc. Strategic partnerships between pharma and device companies are accelerating the integration of therapeutic and interventional care models. As risk stratification protocols, outpatient management, and precision medicine approaches mature, the pulmonary embolism therapeutics market is poised for robust growth across both pharmacological and procedural domains.

Report Scope

The report analyzes the Pulmonary Embolism Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Administration Route (Oral Administration, Parenteral Administration); Application (Hospitals Application, Ambulatory Surgery Centers Application, Research Institutes Application)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Oral Administration segment, which is expected to reach US$32.2 Billion by 2032 with a CAGR of a 12.9%. The Parenteral Administration segment is also set to grow at 9.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $6.0 Billion in 2025, and China, forecasted to grow at an impressive 15.4% CAGR to reach $10.1 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Pulmonary Embolism Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pulmonary Embolism Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Pulmonary Embolism Therapeutics Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Acticor Biotech SAS, Anthos Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Pulmonary Embolism Therapeutics market report include:

• Acticor Biotech SAS
• Anthos Therapeutics, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc. (Roche subsidiary)
• Gilead Sciences, Inc.
• Inari Medical, Inc.
• Johnson & Johnson Services, Inc.
• Medtronic plc
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Ltd.
• Viatris Inc.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.